RxDoctor Payments Data

Tonjeh Bah, MD

Internal Medicine · Cleveland, OHNPI 1215370333

Payments from drug & device makers

$100,174in general payments, 2019–2025

Across 24 payments — averaging $4173.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$88K
  • Bristol Myers Squibb$11K
  • Astellas Pharma US Inc$209
  • Merck$118
  • Amgen$40
  • Pharmacyclics LLC, An Abbvie Company$37
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$26859%
  • Education$19041%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$100,174 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$38,749
Medicare patients
144
Services billed
378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib108$1,529,102
VerzenioAbemaciclib31$456,524
RevlimidLenalidomide19$375,272
JakafiRuxolitinib Phosphate11$287,067
BrukinsaZanubrutinib24$249,190
PomalystPomalidomide15$233,971
XtandiEnzalutamide16$221,474
BosulifBosutinib13$196,145
TagrissoOsimertinib Mesylate11$164,319
ErivedgeVismodegib13$108,610
CalquenceAcalabrutinib Maleate11$101,937
GleevecImatinib Mesylate12$85,190
Abiraterone Acetate36$70,379
Imatinib Mesylate11$51,709
Herceptin HylectaTrastuzumab-Hyaluronidase-Oysk11$48,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$11,267$375,27219 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$88,449$233,97115 claims
Astellas Pharma US IncXtandi$209$221,47416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →